Meeting
2019 Genitourinary Cancers Symposium
A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
Authors
Michael J. Morris
Memorial Sloan Kettering Cancer Center, New York, NY
Michael J. Morris , Ronald De Wit , Nicholas J. Vogelzang , Scott T. Tagawa , Celestia S. Higano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT03574571
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr TPS348)
DOI
10.1200/JCO.2019.37.7_suppl.TPS348
Abstract #
TPS348
Poster Bd #
P2
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
First Author: Michael J. Morris
Poster
2020 ASCO Virtual Scientific Program
A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
First Author: Michael J. Morris
Poster
2021 Genitourinary Cancers Symposium
A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).
First Author: Neeraj Agarwal
Poster
2021 Genitourinary Cancers Symposium
18F-fluciclovine positron emission tomography (PET) in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate.
First Author: Pedro C. Barata